{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:21:53Z","timestamp":1783538513708,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Objectives: Carbapenem-resistant Enterobacterales (CRE) limit treatment options, and cefiderocol\u2019s efficacy can be compromised by regional carbapenemases. In this study, we aimed to characterize cefiderocol susceptibility distribution among Enterobacterales in Japan\u2014specifically endemic strains producing IMP-type carbapenemases (IMP)\u2014and explore the effect of IMP in mediating resistance. Methods: The susceptibility of 556 evaluable Enterobacterales isolates (from an initial 560 screened) to cefiderocol was assessed using disk diffusion and broth microdilution methods based on Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) distributions across groups were compared using Kruskal\u2013Wallis and Mann\u2013Whitney U tests. Results: A total of 556 isolates yielded evaluable results. The cefiderocol susceptibility rate was 99.5 and 98.7% based on CLSI and European Committee on Antimicrobial Susceptibility Testing breakpoints, respectively. Notably, under both criteria, IMP-producing isolates exhibited a susceptibility rate of 99.6%, whereas non-CRE and non-extended-spectrum \u03b2-lactamase (ESBL) exhibited a susceptibility rate of 99.4%. Statistical analysis revealed that the ESBL-only group had higher MICs than the non-CRE\/non-ESBL and IMP-only groups (both p &lt; 0.001), whereas no significant difference was observed between the latter two (p = 0.083). Notably, the ESBL-only group exhibited higher MICs than those of isolates harboring both IMP and ESBL. Conclusions: These findings indicate a non-additive effect, in which the coexistence of multiple resistance enzymes does not necessarily increase cefiderocol resistance. The association between IMP and cefiderocol resistance may be limited. In specific enzyme combinations, its presence was even associated with lower MICs.<\/jats:p>","DOI":"10.3390\/antibiotics15070667","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:27:31Z","timestamp":1783531651000},"page":"667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefiderocol Susceptibility in Japanese Clinical Enterobacterales Isolates and the Effect of IMP-Type Carbapenemases on Resistance"],"prefix":"10.3390","volume":"15","author":[{"given":"Manke","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8007-3215","authenticated-orcid":false,"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"},{"name":"Department of Transformative Protection to Infectious Disease, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"},{"name":"Osaka Institute of Public Health, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The University of Osaka Hospital, 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6864-3788","authenticated-orcid":false,"given":"Ryuji","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Osaka Institute of Public Health, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motooka","sequence":"additional","affiliation":[{"name":"Research Institute for Microbial Diseases, The University of Osaka, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-8955","authenticated-orcid":false,"given":"Satoshi","family":"Kutsuna","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"ref_2","first-page":"e000197","article-title":"Extended-spectrum \u03b2-lactamase-producing and carbapenemase-producing Enterobacteriaceae","volume":"4","author":"Wilson","year":"2018","journal-title":"Microb. Genom."},{"key":"ref_3","first-page":"25","article-title":"Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance","volume":"83","author":"Khanbabaei","year":"2025","journal-title":"Curr. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_8","unstructured":"Shionogi & Co., Ltd. (2026, June 05). Fetcroja (Cefiderocol) Prescribing Information. Available online: https:\/\/www.shionogi.com\/wp-content\/themes\/pdfs\/fetroja.pdf."},{"key":"ref_9","unstructured":"Shionogi & Co., Ltd. (2026, June 05). Fetcroja. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"ref_10","unstructured":"Shionogi & Co., Ltd. (2026, June 05). New Siderophore Cephalosporin Antibiotic Fetroja (Cefiderocol) Intravenous Infusion 1g Vial in Japan [Press Release]. Available online: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/12\/20231220.html."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0199021","DOI":"10.1128\/AAC.01990-21","article-title":"In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ohkura, T., Watarai, R., Takekoshi, M., Ohara, M., Osada, Y., Morioka, H., Iguchi, M., Oka, K., and Yagi, T. (2026). Susceptibility to cefiderocol and other novel antibiotics against carbapenem-non-susceptible gram-negative bacilli. Jpn. J. Infect. Dis., in press.","DOI":"10.7883\/yoken.JJID.2025.170"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117138","DOI":"10.1016\/j.diagmicrobio.2025.117138","article-title":"In vitro activity of essential antimicrobial agents, including ceftazidime\/avibactam, imipenem\/relebactam, and cefiderocol, against carbapenem-resistant Gram-negative bacteria primarily harboring the IMP-type carbapenemase gene in the Kinki region of Japan","volume":"114","author":"Kuchibiro","year":"2026","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1128\/AAC.00818-13","article-title":"Characterization of the new AmpC \u03b2-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis","volume":"57","author":"Kerff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00198-20","DOI":"10.1128\/AAC.00198-20","article-title":"Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2666-5247(21)00098-7","article-title":"Uncovering the novel Enterobacter cloacae complex species responsible for septic shock deaths in newborns: A cohort study","volume":"2","author":"Girlich","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00002-19","DOI":"10.1128\/CMR.00002-19","article-title":"Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance","volume":"32","author":"Lavigne","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e0248524","DOI":"10.1128\/spectrum.02485-24","article-title":"Molecular epidemiology and \u03b2-lactam resistance mechanisms of Enterobacter cloacae complex isolates obtained from bloodstream infections, Kyoto, Japan","volume":"13","author":"Matsuo","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/jcm.32.5.1373-1375.1994","article-title":"Comparison of three methods for determination of a single MIC of an antimicrobial agent","volume":"32","author":"Miller","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0535522","DOI":"10.1128\/spectrum.05355-22","article-title":"Assessment of cefiderocol disk diffusion versus broth microdilution results when tested against Acinetobacter baumannii complex clinical isolates","volume":"11","author":"Liu","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/AAC.45.5.1343-1348.2001","article-title":"Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem","volume":"45","author":"Yano","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.diagmicrobio.2011.09.019","article-title":"Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6","volume":"72","author":"Shigemoto","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00490-20","DOI":"10.1128\/mSphere.00490-20","article-title":"Molecular and Epidemiological Characteristics of Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates in Japan","volume":"5","author":"Yonekawa","year":"2020","journal-title":"mSphere"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hirabayashi, A., Yahara, K., Kajihara, T., Sugai, M., and Shibayama, K. (2020). Geographical distribution of Enterobacterales with a carbapenemase IMP-6 phenotype and its association with antimicrobial use: An analysis using comprehensive national surveillance data on antimicrobial resistance. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243630"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00951-20","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles\u2019 Heel of the Trojan Horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2024). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [34th ed.]. CLSI Supplement M100."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01649-20","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution","volume":"59","author":"Morris","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_31","unstructured":"Duggan, C., Cantillon, D., Lawrie, D., Neal, T., Cruise, J., Graf, F.E., Owen, V., Fraser, A.J., Lewis, J.M., and Brookfield, C. (2026). Comparison of multiple cefiderocol susceptibility testing methods against genomic determinants of resistance in blaNDM carbapenemase producing Enterobacterales. bioRxiv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ofac492.1351","DOI":"10.1093\/ofid\/ofac492.1351","article-title":"In Vitro Activity of Cefiderocol against IMP-Producing Enterobacterales Isolated in Japan","volume":"9","author":"Yamashiro","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/ofid\/ofaa439.1436","article-title":"In Vitro Activity of Cefiderocol Against Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014\u20132016 Studies","volume":"7","author":"Takemura","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102905","DOI":"10.1016\/j.jiac.2026.102905","article-title":"In vitro activity of cefiderocol against carbapenem-resistant Gram-negative pathogens in Japan","volume":"32","author":"Matsui","year":"2026","journal-title":"J. Infect. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01505-22","DOI":"10.1128\/aac.01505-22","article-title":"Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-\u03b2-Lactamase VIM-1","volume":"67","author":"Outeda","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkae326","article-title":"Impact of transferable \u03b2-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa","volume":"79","author":"Beceiro","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.tim.2018.06.007","article-title":"Evolution of Plasmid-Mediated Antibiotic Resistance in the Clinical Context","volume":"26","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: Is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e0125525","DOI":"10.1128\/jcm.01255-25","article-title":"Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration","volume":"64","author":"Lin","year":"2026","journal-title":"J. Clin. Microbiol."},{"key":"ref_41","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2026). Breakpoint Tables for Interpretation of MICs and Zone Diameters, EUCAST. Version 16.0."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"dlae169","DOI":"10.1093\/jacamr\/dlae169","article-title":"Real-world performance of susceptibility testing for cefiderocol: Insights from a prospective multicentre study on Gram-negative bacteria","volume":"6","author":"Cercenado","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wick, R.R., Judd, L.M., Gorrie, C.L., and Holt, K.E. (2017). Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005595"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/bioinformatics\/btx713","article-title":"DFAST: A flexible prokaryotic genome annotation pipeline for faster genome publication","volume":"34","author":"Tanizawa","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.1038\/s41598-021-91456-0","article-title":"AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence","volume":"11","author":"Feldgarden","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D690","DOI":"10.1093\/nar\/gkac920","article-title":"CARD 2023: Expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database","volume":"51","author":"Alcock","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:55:10Z","timestamp":1783533310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["antibiotics15070667"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15070667","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}